Brokerages Give Allogene Therapeutics, Moderate Buy Rating: Bloomberg Report
Trending News 🌥️ Allogene Therapeutics ($NASDAQ:ALLO), Inc., a clinical-stage biotechnology company, is focused on developing allogeneic chimeric antigen receptor T [...]
Allogene Therapeutics: A Must-Watch Stock in the Coming Weeks
Trending News 🌥️ Allogene Therapeutics ($NASDAQ:ALLO) is a publicly traded biopharmaceutical company that focuses on developing novel, allogeneic cell therapies [...]
ALLOGENE THERAPEUTICS to Present at 41st Annual J.P. Morgan Healthcare Conference in 2023
Trending News 🌥️ Allogene Therapeutics ($NASDAQ:ALLO) is a clinical-stage biotechnology company that focuses on the development of allogeneic chimeric antigen [...]
Allogene Therapeutics Experiences Steep Loss in Recent Trading Session
Trending News 🌧️ Allogene Therapeutics ($NASDAQ:ALLO), Inc. is a clinical-stage biopharmaceutical company. The company focuses on the development of allogeneic [...]
Allogene Therapeutics Reassesses Changing Outlook
Trending News 🌥️ Allogene Therapeutics ($NASDAQ:ALLO) Inc. is a company that is dedicated to developing immunotherapies to treat cancer. The [...]
Allogene Therapeutics Initiates Phase 2 Trial of ALLO-501A for Relapsed/Refractory Large B-Cell Lymphoma
Trending News 🌥️ Allogene Therapeutics ($NASDAQ:ALLO) is a clinical-stage biopharmaceutical company focused on developing allogeneic CAR T cell therapies for [...]
